Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
作者信息
Gambacorti-Passerini Carlo, Nicolini Franck Emmanuel, Larson Richard A, Aroldi Andrea, Fontana Diletta, Piazza Rocco, le Coutre Philipp, Antolini Laura, Assouline Sarit
机构信息
Hematology Division, ASST Monza, Monza, Italy.
University of Milano-Bicocca, Monza, Italy.
出版信息
Am J Hematol. 2022 Aug;97(8):E296-E298. doi: 10.1002/ajh.26618. Epub 2022 Jun 9.
Abstract
摘要
相似文献
1
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.使用第二代酪氨酸激酶抑制剂时需谨慎，尤其是用于慢性髓性白血病的一线治疗时。
Am J Hematol. 2022 Aug;97(8):E296-E298. doi: 10.1002/ajh.26618. Epub 2022 Jun 9.
2
Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?酪氨酸激酶抑制剂（TKI）用于新诊断慢性髓性白血病患者的治疗：聚焦因不良事件导致的TKI停药——总是更好就好吗？
Expert Rev Hematol. 2017 Jul;10(7):583-586. doi: 10.1080/17474086.2017.1339599. Epub 2017 Jun 13.
3
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
4
5
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.慢性粒细胞白血病中的新型酪氨酸激酶抑制剂
Curr Opin Oncol. 2006 Nov;18(6):578-83. doi: 10.1097/01.cco.0000245314.97638.d3.
6
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.BCR-ABL 酪氨酸激酶抑制剂治疗费城染色体阳性慢性髓性白血病：综述。
Leuk Res. 2010 Oct;34(10):1255-68. doi: 10.1016/j.leukres.2010.04.016.
7
[Nilotinib as a second-line treatment for chronic myeloid leukemia].尼洛替尼作为慢性髓性白血病的二线治疗药物
Gan To Kagaku Ryoho. 2011 Jun;38(6):911-5.
8
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.慢性髓性白血病中酪氨酸激酶抑制剂相关毒性的实际管理
Clin Lymphoma Myeloma. 2008 Mar;8 Suppl 3:S82-8. doi: 10.3816/CLM.2008.s.003.
9
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.接受新一代BCR-ABL酪氨酸激酶抑制剂治疗的慢性髓性白血病患者发生动脉和静脉闭塞事件的风险：一项系统评价和荟萃分析。
Expert Opin Drug Saf. 2017 Jan;16(1):5-12. doi: 10.1080/14740338.2017.1261824. Epub 2016 Nov 28.
10
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?对于在伊马替尼初始标准剂量治疗下反应欠佳的慢性髓性白血病患者，换用第二代酪氨酸激酶抑制剂或增加伊马替尼剂量是否具有长期益处？
Leuk Res. 2018 Nov;74:55-56. doi: 10.1016/j.leukres.2018.09.013. Epub 2018 Sep 29.
引用本文的文献
1
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.真实世界中使用波那替尼治疗慢性期慢性髓性白血病的经验：反应深度对生存的影响以及先前使用尼洛替尼对动脉闭塞事件的影响。
Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x.
本文引用的文献
1
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.酪氨酸激酶抑制剂在慢性髓性白血病中的停药：适应证标准和成功预测因素。
Am J Hematol. 2022 Aug;97(8):1075-1085. doi: 10.1002/ajh.26556. Epub 2022 Apr 12.
2
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的不良结局：在一项全覆盖且全国性的未知登记研究中对 2002-2017 年确诊的患者进行随访。
Am J Hematol. 2022 Apr;97(4):421-430. doi: 10.1002/ajh.26463. Epub 2022 Jan 20.
3
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.骨髓增殖性肿瘤患者的二次恶性肿瘤：一项基于人群的 9379 例患者的队列研究。
Leukemia. 2018 Oct;32(10):2203-2210. doi: 10.1038/s41375-018-0027-y. Epub 2018 Jan 30.
4
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.慢性髓性白血病中BCR-ABL酪氨酸激酶抑制剂的心血管毒性：预防策略与心血管监测
Vasc Health Risk Manag. 2017 Aug 4;13:293-303. doi: 10.2147/VHRM.S108874. eCollection 2017.
5
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.慢性髓性白血病患者的预期寿命接近普通人群。
J Clin Oncol. 2016 Aug 20;34(24):2851-7. doi: 10.1200/JCO.2015.66.2866. Epub 2016 Jun 20.
6
First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.102 例慢性髓性白血病患者伊马替尼一线治疗：长期单中心分析。
Am J Hematol. 2014 Oct;89(10):E184-7. doi: 10.1002/ajh.23804. Epub 2014 Jul 31.
7
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.大多数接受伊马替尼治疗的患者达到了深度分子反应，该反应可预测生存，并且通过优化的高剂量伊马替尼更快实现：来自随机 CML-研究 IV 的结果。
J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.
8
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.慢性骨髓增生性肿瘤与后续癌症风险：丹麦基于人群的队列研究。
Blood. 2011 Dec 15;118(25):6515-20. doi: 10.1182/blood-2011-04-348755. Epub 2011 Oct 28.
9
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.多中心独立评估伊马替尼治疗慢性髓性白血病患者的结局。
J Natl Cancer Inst. 2011 Apr 6;103(7):553-61. doi: 10.1093/jnci/djr060. Epub 2011 Mar 21.
10
Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.慢性髓性白血病患者发生第二恶性肿瘤的风险更高吗？一项基于人群的研究。
Am J Epidemiol. 2010 Nov 1;172(9):1028-33. doi: 10.1093/aje/kwq262. Epub 2010 Sep 22.
Zotero 插件